Karyopharm Therapeutics Inc. (KPTI) Total liabilities 2016–2025
Karyopharm Therapeutics Inc. (KPTI) total liabilities at each fiscal year-end, per SEC filings.
$401.3MFY2025 · since FY2016: $18.1M → $401.3M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $401.3M | +14.5% |
| FY2024 | $350.4M | -7.0% |
| FY2023 | $376.6M | +0.5% |
| FY2022 | $374.8M | -2.6% |
| FY2021 | $385.0M | +46.7% |
| FY2020 | $262.5M | +7.1% |
| FY2019 | $245.2M | +55.2% |
| FY2018 | $158.0M | +210.9% |
| FY2017 | $50.8M | +180.2% |
| FY2016 | $18.1M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice